Does cilengitide deserve another chance?-Authors' reply

Roger Stupp; Martin Picard; Michael Weller

doi:10.1016/S1470-2045(14)71121-0

Does cilengitide deserve another chance?-Authors' reply

Roger Stupp^*, Martin Picard, Michael Weller

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	e585-e586
Journal	The Lancet Oncology
Volume	15
Issue number	13
DOIs	https://doi.org/10.1016/S1470-2045(14)71121-0
State	Published - 2014

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(14)71121-0

Cite this

@article{df3260c9d6a04746aef2d919701ff335,

title = "Does cilengitide deserve another chance?-Authors' reply",

author = "Roger Stupp and Martin Picard and Michael Weller",

note = "Funding Information: RS declares expenses in relationship with the study from Merck KGaA and has served on advisory boards for Roche, MSD/Merck & Co, and Novartis. MP is employed by Merck KGaA. MW declares consultant or advisory roles for Isarna, Merck Serono, Roche, and Magforce, personal fees from Merck Serono, Roche, MSD, and Magforce, and research funding from Bayer, Merck Serono, Roche, MSD, and Isarna. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.",

year = "2014",

doi = "10.1016/S1470-2045(14)71121-0",

language = "English (US)",

volume = "15",

pages = "e585--e586",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "13",

}

TY - JOUR

T1 - Does cilengitide deserve another chance?-Authors' reply

AU - Stupp, Roger

AU - Picard, Martin

AU - Weller, Michael

N1 - Funding Information: RS declares expenses in relationship with the study from Merck KGaA and has served on advisory boards for Roche, MSD/Merck & Co, and Novartis. MP is employed by Merck KGaA. MW declares consultant or advisory roles for Isarna, Merck Serono, Roche, and Magforce, personal fees from Merck Serono, Roche, MSD, and Magforce, and research funding from Bayer, Merck Serono, Roche, MSD, and Isarna. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.

PY - 2014

Y1 - 2014

UR - http://www.scopus.com/inward/record.url?scp=84925228279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925228279&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)71121-0

DO - 10.1016/S1470-2045(14)71121-0

M3 - Letter

C2 - 25456377

AN - SCOPUS:84925228279

VL - 15

SP - e585-e586

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 13

ER -

Does cilengitide deserve another chance?-Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this